Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 7.2% in the last trading session to close at $10.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock’s 45.3% gain over the past four weeks.
Silence Therapeutics’ share price gain can likely be attributed to the growing investor optimism around the company’s advancing RNA interference (siRNA) pipeline, upcoming clinical data readouts, and the long-term growth potential of its lead candidate, divesiran. The ongoing phase II SANRECO study evaluating divesiran in patients with polycythemia vera (PV) is expected to report topline results in August 2026, which could serve as a key near-term catalyst. Meanwhile, the company is actively seeking a strategic partner to support the late-stage development and commercialization of zerlasiran, its phase III-ready siRNA candidate for cardiovascular disease associated with elevated lipoprotein(a) [Lp(a)]. In addition, Silence Therapeutics is set to regain global rights to SLN312 after AstraZeneca decided to discontinue further development of the program, providing the company with an opportunity to evaluate future development and partnering options.
This company is expected to post quarterly loss of $0.32 per share in its upcoming report, which represents a year-over-year change of +40.7%. Revenues are expected to be $3.14 million, up 1325% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Silence Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SLN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Silence Therapeutics belongs to the Zacks Medical – Drugs industry. Another stock from the same industry, Merck KGaA (MKKGY), closed the last trading session 1.3% higher at $32.25. Over the past month, MKKGY has returned 3.7%.
For Merck KGaA, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.47. This represents a change of -17.5% from what the company reported a year ago. Merck KGaA currently has a Zacks Rank of #2 (Buy).
Zacks’ Research Chief Names “Stock Most Likely to Double”
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company’s customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Silence Therapeutics PLC Sponsored ADR (SLN) : Free Stock Analysis Report
Merck KGaA (MKKGY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
